Galenfeha, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Galenfeha, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $280.1K | Apr 16, 2015 |
| FY2013 | Dec 31, 2013 | $0 | Mar 27, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $331.7K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $66.4K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Apr 16, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | ($162.6K) | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | ($1.28M) | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | ($1.60M) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($474.0K) | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $136.5K | Apr 16, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | ($94.9K) | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | ($597.7K) | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | ($440.7K) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($453.0K) | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | ($136.5K) | Mar 27, 2014 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.8K | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 28, 2018 |
| FY2015 | Dec 31, 2015 | $174.5K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $58.8K | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | $12.3K | Mar 27, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | ($97.3K) | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | ($393.2K) | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | ($1.35M) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | ($671.2K) | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | ($130.7K) | Mar 27, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $73.1K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $187.9K | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | $8.4K | Mar 27, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $55.0K | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | $526.2K | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $1.71M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $598.7K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $92.5K | Apr 16, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $122.4K | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | $536.5K | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | $672.1K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $221.4K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $5.2K | Apr 16, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | ($67.4K) | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | ($10.3K) | Mar 28, 2018 |
| FY2017 | Dec 31, 2015 | $1.04M | Mar 28, 2018 |
| FY2016 | Dec 31, 2014 | $377.3K | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $87.3K | Mar 30, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $389.8K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 30, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | ($3.65M) | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | ($3.49M) | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | ($2.21M) | Mar 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $469 | Mar 28, 2018 |
| FY2017 | Dec 31, 2016 | $130.0K | Mar 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.64M | May 22, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 72.30M | May 22, 2019 |
| FY2018 | Dec 31, 2017 | 72.30M | May 22, 2019 |
| FY2017 | Dec 31, 2016 | 69.32M | Mar 28, 2018 |
| FY2016 | Dec 31, 2015 | 86.13M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | 77.81M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | 51.25M | Apr 16, 2015 |